Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Tirzepatide is a dual agonist (GIP and GLP-1), which clinical trials indicate causes greater weight loss (up to 20-21%) than the GLP-1-only agonist Semaglutide (around 15%), though both are effective tools for managing obesity
Export data summaries for healthcare appointments to facilitate discussions about treatment adjustments
Increased Fat Storage Efficiency During perceived recovery from restriction, the body may preferentially store energy
Medications, including semaglutide, come with expiration dates for a reason
Talk to your healthcare provider to see if Rybelsus fits into your treatment plan
US$ 23.77
US$ 25.58
:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)
US$ 29.96
